Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3302997 | 1.00 | PNP (0.81) | PNPHPRT1 | |
| SCHEMBL12300507 | 0.87 | PNP (0.63) | PNPHPRT1 | |
| SCHEMBL1738240 | 0.87 | PNP (0.63) | PNPHPRT1 | |
| SCHEMBL16199362 | 0.87 | PNP (0.63) | PNPHPRT1 | |
| SCHEMBL6727247 | 0.87 | PNP (0.63) | PNPHPRT1 | |
| SCHEMBL10858597 | 0.80 | PNP (0.53) | PNP | |
| SCHEMBL3305081 | 0.80 | PNP (0.80) | PNP | |
| SCHEMBL3305072 | 0.80 | PNP (0.80) | PNP | |
| SCHEMBL17834719 | 0.80 | PNP (0.62) | PNPHPRT1 | |
| SCHEMBL12729546 | 0.80 | PNP (0.62) | PNPHPRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093991-A1 | METHODS FOR THE PREPARATION OF 9-DEAZAPURINE DERIVATIVES | BIO CRYST PHARMACEUTICALS , INC. (US) | 2010-04-15 | — | — | US | claimed |
| US-8344132-B2 | Methods for the preparation of 9-deazapurine derivatives | BioCryst Pharmaceticals, Inc. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8344132-B2 | Methods for the preparation of 9-deazapurine derivatives | BioCryst Pharmaceticals, Inc. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8344132-B2 | Methods for the preparation of 9-deazapurine derivatives | BioCryst Pharmaceticals, Inc. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20100093991-A1 | METHODS FOR THE PREPARATION OF 9-DEAZAPURINE DERIVATIVES | BIO CRYST PHARMACEUTICALS , INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100093991-A1 | METHODS FOR THE PREPARATION OF 9-DEAZAPURINE DERIVATIVES | BIO CRYST PHARMACEUTICALS , INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100093991-A1 | METHODS FOR THE PREPARATION OF 9-DEAZAPURINE DERIVATIVES | BIO CRYST PHARMACEUTICALS , INC. (US) | 2010-04-15 | — | — | US | disclosed |
| EP-0543004-A1 | PURINE BASE MODIFIED 2'-DEOXYRIBONUCLEOSIDES, USE IN TRIPLEX FORMING OLIGONUCLEOTIDES AND PROCESS FOR PREPARING THE SAME | TRIPLEX PHARMACEUTICAL CORPORATION (US) | 1993-05-26 | — | — | EP | disclosed |
| WO-1992021690-A1 | PURINE BASE MODIFIED 2'-DEOXYRIBONUCLEOSIDES, USE IN TRIPLEX FORMING OLIGONUCLEOTIDES AND PROCESS FOR PREPARING THE SAME | TRIPLEX PHARMACEUTICAL CORPORATION (US) | 1992-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093991-A1 | METHODS FOR THE PREPARATION OF 9-DEAZAPURINE DERIVATIVES | DPYD, TYMP, UNG | PNP 8/4885HPRT1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.